Encounter for antenatal screening for raised alphafetoprotein level
ICD-10 Z36.1 is a billable code used to indicate a diagnosis of encounter for antenatal screening for raised alphafetoprotein level.
Z36.1 is used to indicate an encounter for antenatal screening specifically aimed at detecting elevated levels of alpha-fetoprotein (AFP) in pregnant individuals. Elevated AFP levels can be associated with various fetal conditions, including neural tube defects and chromosomal abnormalities. This screening is a crucial preventive measure in prenatal care, allowing for early detection and management of potential health issues. Social determinants of health, such as access to healthcare, socioeconomic status, and education, significantly influence the likelihood of receiving appropriate screening. Preventive care through regular antenatal visits ensures that expectant mothers are monitored for AFP levels, which can lead to timely interventions and improved maternal and fetal outcomes. The screening process involves counseling, education about the implications of results, and potential follow-up testing, emphasizing the importance of comprehensive care in the prenatal period.
Documentation must include the reason for screening, results, and any follow-up plans or referrals.
Routine prenatal visits where AFP screening is discussed and performed.
Consideration of social determinants such as access to care and patient education on the importance of screening.
Data collection for population health management and tracking of screening rates.
Community health initiatives aimed at increasing awareness and access to prenatal screenings.
Focus on health disparities and outreach efforts to underserved populations.
Used during routine prenatal visits for screening purposes.
Document the reason for the test, results, and any follow-up actions.
Primary care providers should ensure comprehensive patient education regarding the implications of results.
Elevated AFP levels can indicate potential fetal abnormalities, such as neural tube defects or chromosomal issues. It is crucial for healthcare providers to educate patients about the implications of these results and the importance of follow-up testing.
